Minoxidil sulfotransferase enzymatical activity in plants: A novel paradigm in increasing minoxidil response in androgenetic alopecia

J Cosmet Dermatol. 2024 Jan;23(1):339-343. doi: 10.1111/jocd.15980. Epub 2023 Aug 28.

Abstract

Background: Minoxidil is the only US FDA approved topical drug for the treatment of androgenetic alopecia (AGA). Minoxidil is effective in hair re-growth in 30%-40% of patients and 50% of males. To exert its hair growing effect, minoxidil must be sulfonated in the scalp by the minoxidil sulfotransferase enzyme (SULT1A1). Low scalp SULT1A1 correlates with lack of minoxidil response; thus, supplementing the scalp SULT1A1 with naturally occurring minoxidil sulfotransferase enzymes could potentially improve treatment outcomes in AGA patients.

Methods: In this study, we set to characterize SULT1A1 activity in various plants.

Results: From the 10 common botanical extracts we have studied, seven exhibited significant activity toward minoxidil as a substrate; thus, providing a potential novel paradigm to increase minoxidil response with natural supplements.

Conclusion: To the best of our knowledge, this is the first study to characterize naturally occurring minoxidil sulfotransferase enzymes in plants.

Keywords: alopecia; androgenic alopecia; botanicals; hair loss; minoxidil; sulfotransferase; treatment.

MeSH terms

  • Administration, Topical
  • Alopecia* / chemically induced
  • Alopecia* / drug therapy
  • Humans
  • Male
  • Minoxidil* / therapeutic use
  • Sulfotransferases / therapeutic use
  • Treatment Outcome

Substances

  • Minoxidil
  • minoxidil sulfotransferase
  • Sulfotransferases